Related Experiment Video
Updated: Feb 1, 2026

In Vitro Rearing of Solitary Bees: A Tool for Assessing Larval Risk Factors
Published on: July 16, 2018
JCL roundtable-Lipoprotein(a): The emerging risk factor
Santica M Marcovina1, Patrick M Moriarty2, Marlys L Koschinsky3
1University of Washington, Seattle, WA, USA.
Insights
Lipoprotein(a) (Lp(a)) is a key risk factor for cardiovascular events and calcific aortic stenosis. Emerging therapies show promise in significantly lowering Lp(a) levels, offering new clinical strategies.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Pharmacology
Background:
- Lipoprotein(a) (Lp(a)) is a significant risk factor for atherothrombotic events, comparable to LDL cholesterol.
- Lp(a) is implicated in the progression of calcific aortic stenosis and arterial strokes, even without atherosclerosis.
- Understanding Lp(a) inheritance and apolipoprotein(a) structure-function is advancing.
Purpose of the Study:
- To review the role of Lipoprotein(a) in cardiovascular diseases.
- To explore the interaction between Lp(a), oxidized phospholipids, and inflammatory markers.
- To discuss novel pharmaceutical strategies for Lp(a) reduction and clinical management.
Main Methods:
- Review of current literature on Lp(a) genetics, function, and clinical impact.
- Discussion of recent findings on Lp(a) interactions with inflammatory pathways.
- Analysis of emerging antisense and RNA interference technologies for Lp(a) lowering.
Main Results:
- Lp(a) levels are strongly inherited, with apolipoprotein(a) structure influencing function.
- Interactions between oxidized phospholipids on Lp(a) and interleukin-1 genotypes are observed.
- New therapies, including antisense and RNA interference, can reduce Lp(a) by up to 90%.
Conclusions:
- Lipoprotein(a) is a critical, actionable target for cardiovascular risk reduction.
- Novel therapeutic approaches offer unprecedented potential for lowering Lp(a) levels.
- Clinical measurement and management strategies for Lp(a) are evolving.
Abstract:
Lipoprotein(a), or Lp(a), is a major risk factor for atherothrombotic events along with low-density lipoprotein cholesterol and, inversely, high-density lipoprotein cholesterol. Lp(a) also contributes to the progression of calcific aortic stenosis and to the rare occurrence of arterial thrombotic strokes without atherosclerosis in children and younger women. Much has been learned about the inheritance of Lp(a) levels and the relationship between apolipoprotein(a) structure and function. Recent work suggests an intriguing interaction between oxidized phospholipids on Lp(a) and inflammatory interleukin-1 genotypes. New pharmaceutical approaches with antisense and RNA interference technology may achieve up to 90% lowering of Lp(a). This Roundtable includes practical considerations for clinically measuring and responding to Lp(a) levels.
Related Concept Videos
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Emerging Adulthood
Relative Risk
Introduction Cardiac Emergencies
Transcription Factors
Applications of GIS: Disaster Management and Emergency Response

